Microsatellite Instability (MSI) Detection Kit

About EntroGen

EntroGen is a privately held, commercial-stage diagnostics company founded in 2008 and headquartered in Woodland Hills, California. The company has established a commercial footprint with its FDA-approved companion diagnostic for KRAS/NRAS mutations in colorectal cancer and is expanding its portfolio with RUO kits for minimal residual disease (MRD) and microsatellite instability (MSI). EntroGen's strategy centers on providing end-to-end, automated molecular diagnostic solutions to support personalized treatment decisions in oncology.

Therapeutic Areas